AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11463595 — intervention group
Group type: EXPERIMENTAL
Intervention: NO inhalation at 5 ppm in supine position (SP + NO)
Number of subjects: 15
Study 11463595 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position (PP)
Number of subjects: 15
Study 11463595 — intervention group
Group type: EXPERIMENTAL
Intervention: NO inhalation in supine position (SP + NO) for Pu ARDS
Number of subjects: 15
Study 11463595 — intervention group
Group type: EXPERIMENTAL
Intervention: NO inhalation in prone position (PP + NO) for Pu ARDS
Number of subjects: 15
Study 11463595 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position (PP) for Epu ARDS
Number of subjects: 15
Study 9529407 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ultrasound treatment (1 MHz, 1.0 W/cm2, pulsed mode 1:4, 15 minutes per session)
Number of subjects: 45
Study 9529407 — intervention group
Group type: COMPARATOR
Intervention: Sham ultrasound treatment
Number of subjects: 45
Study 9143885 — intervention group
Group type: EXPERIMENTAL
Intervention: Botox (45.4 IU average, range 25-85 IU)
Number of subjects: 212
Study 9143885 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport (182.1 IU average, range 100-340 IU)
Number of subjects: 212
Study 9143885 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Botox and Dysport
Number of subjects: 212
Study 2015918 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI stage
Number of subjects: 11
Study 2015918 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical stage
Number of subjects: 11
Study 2015918 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI assessment of parametrial and lymph-node involvement
Number of subjects: 11
Study 6925101 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity-centered health curriculum
Number of subjects: 20
Study 6925101 — intervention group
Group type: COMPARATOR
Intervention: Control group (no new health program)
Number of subjects: 20
Study 30914378 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal metabolites associated with asthma, including polyunsaturated fatty acids.
Number of subjects: 361
Study 30914378 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breast-feeding for the first 4 months of life.
Number of subjects: 361
Study 30914378 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet rich in meats.
Number of subjects: 361
Study 30914378 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific intestinal bacterial taxa (Christensenellaceae) and plasma metabolites (γ-tocopherol/β-tocopherol).
Number of subjects: 361
Study 30220610 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 30mg
Number of subjects: 18
Study 30220610 — intervention group
Group type: COMPARATOR
Intervention: Control group (no glucocorticoid or placebo)
Number of subjects: 18
Study 27014353 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/Valsartan 5/160 mg
Number of subjects: 0
Study 27014353 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 10 mg
Number of subjects: 0
Study 24762683 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day triple regimen (rabeprazole 10 mg, amoxicillin 1000 mg, furazolidone 100 mg twice daily for 7 days)
Number of subjects: 357
Study 24762683 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day triple regimen (rabeprazole 10 mg, amoxicillin 1000 mg, furazolidone 100 mg twice daily for 10 days)
Number of subjects: 357
Study 24762683 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day quadruple regimen (rabeprazole 10 mg, bismuth 220 mg, amoxicillin 1000 mg, furazolidone 100 mg twice daily for 7 days)
Number of subjects: 357
Study 24762683 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day quadruple regimen (rabeprazole 10 mg, bismuth 220 mg, amoxicillin 1000 mg, furazolidone 100 mg twice daily for 10 days)
Number of subjects: 357
Study 24762683 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as the comparison between triple and quadruple regimens)
Number of subjects: 357
Study 22802030 — intervention group
Group type: EXPERIMENTAL
Intervention: Experts (photo professionals)
Number of subjects: 118
Study 22802030 — intervention group
Group type: COMPARATOR
Intervention: Inexperienced individuals
Number of subjects: 118
Study 20142631 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin-leptin ratio
Number of subjects: 70
Study 20142631 — intervention group
Group type: COMPARATOR
Intervention: HOMA, QUICKI, fasting glucose/insulin ratio, McAuley index
Number of subjects: 70
Study 19019665 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobra Perilaryngeal Airway
Number of subjects: 180
Study 19019665 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA) Classic
Number of subjects: 180
Study 19019665 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA Fastrach
Number of subjects: 180
Study 19019665 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA ProSeal
Number of subjects: 180
Study 19019665 — intervention group
Group type: EXPERIMENTAL
Intervention: laryngeal tube
Number of subjects: 180
Study 19019665 — intervention group
Group type: EXPERIMENTAL
Intervention: ETT (SIMS Portex, Ltd, Hythe, Kent, UK)
Number of subjects: 180
Study 16078953 — intervention group
Group type: COMPARATOR
Intervention: Typical antipsychotics
Number of subjects: 2005
Study 16078953 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 2005
Study 16078953 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 2005
Study 16078953 — intervention group
Group type: COMPARATOR
Intervention: Antidepressants
Number of subjects: 2005
Study 11850255 — intervention group
Group type: EXPERIMENTAL
Intervention: Amprenavir
Number of subjects: 48
Study 11850255 — intervention group
Group type: COMPARATOR
Intervention: Indinavir
Number of subjects: 48
Study 10052877 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured portal dose images (PDIs) for lateral fields
Number of subjects: 10
Study 10052877 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured portal dose images (PDIs) for anterior fields
Number of subjects: 10
Study 10052877 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of measured and predicted portal doses for lateral fields
Number of subjects: 10
Study 10052877 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of measured and predicted portal doses for anterior fields
Number of subjects: 10
Study 10052877 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-axis differences in measured and predicted portal doses
Number of subjects: 10
Study 10052877 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of gas pockets during treatment
Number of subjects: 10
Study 7525185 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (given alone, in combination with conventional chemotherapy, or as maintenance therapy)
Number of subjects: 0
Study 7525185 — intervention group
Group type: EXPERIMENTAL
Intervention: Myelo-ablative therapy with autologous bone marrow transplantation (with or without in vitro treatment of the marrow)
Number of subjects: 0
Study 7525185 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiolabelled monoclonal antibodies
Number of subjects: 0
Study 7525185 — intervention group
Group type: EXPERIMENTAL
Intervention: Purine analogues (e.g., fludarabine)
Number of subjects: 0
Study 2843040 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated tissues
Number of subjects: 296
Study 2843040 — intervention group
Group type: COMPARATOR
Intervention: Placebo tissues
Number of subjects: 296
Study 29682578 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes group
Number of subjects: 43
Study 29682578 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study 26843588 — intervention group
Group type: EXPERIMENTAL
Intervention: MCCGA (400 mL coffee/d for 8 weeks; 420 mg CGA)
Number of subjects: 75
Study 26843588 — intervention group
Group type: EXPERIMENTAL
Intervention: HCCGA (400 mL coffee/d for 8 weeks; 780 mg CGA)
Number of subjects: 75
Study 26843588 — intervention group
Group type: COMPARATOR
Intervention: Control group (no coffee consumption)
Number of subjects: 75
Study 24789057 — intervention group
Group type: EXPERIMENTAL
Intervention: DMAU 200 mg with food
Number of subjects: 12
Study 24789057 — intervention group
Group type: EXPERIMENTAL
Intervention: DMAU 800 mg with food
Number of subjects: 12
Study 24789057 — intervention group
Group type: EXPERIMENTAL
Intervention: DMAU 800 mg fasting
Number of subjects: 12
Study 24789057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 22447415 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin 10, 25, 50, or 100 µg
Number of subjects: 757
Study 22447415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 757
Study 21409314 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment (two daily injections)
Number of subjects: 34
Study 21409314 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide treatment
Number of subjects: 34
Study 19216444 — intervention group
Group type: COMPARATOR
Intervention: 0.1% bupivacaine continuous drip associated to fentanyl 2 lg/mL (CP‐group)
Number of subjects: 40
Study 19216444 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Controlled Epidural Analgesia (PCEA)
Number of subjects: 40
Study 19216444 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 16148694 — intervention group
Group type: COMPARATOR
Intervention: Serum-free media (SFM)
Number of subjects: 6
Study 16148694 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% fetal bovine serum (FBS)
Number of subjects: 6
Study 16148694 — intervention group
Group type: EXPERIMENTAL
Intervention: FGF-2 and TGF-beta1 (various concentrations)
Number of subjects: 6
Study 16148694 — intervention group
Group type: EXPERIMENTAL
Intervention: BMP-2 and IGF-1 (various concentrations)
Number of subjects: 6
Study 12851623 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional stenting
Number of subjects: 79
Study 12851623 — intervention group
Group type: COMPARATOR
Intervention: No additional stenting
Number of subjects: 79
Study 10099740 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1.8g oral calcium daily)
Number of subjects: 456
Study 10099740 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 456
Study 8678495 — intervention group
Group type: EXPERIMENTAL
Intervention: MMV (mitomycin C + methotrexate + vincristine)
Number of subjects: 102
Study 8678495 — intervention group
Group type: EXPERIMENTAL
Intervention: MMVM (MMV + medroxyprogesterone acetate)
Number of subjects: 102
Study 8678495 — intervention group
Group type: EXPERIMENTAL
Intervention: MMVP (MMV + prednisolone)
Number of subjects: 102
Study 8678495 — intervention group
Group type: COMPARATOR
Intervention: Control (MMV)
Number of subjects: 102
Study 1351620 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD) with amphotericin, colistin, and tobramycin applied to the oropharynx and enterally; all patients received intravenous cefotaxime for 72 hours.
Number of subjects: 239
Study 1351620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study 1351620 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination of the digestive tract (SDD)
Number of subjects: 239
Study 6731167 — intervention group
Group type: EXPERIMENTAL
Intervention: Special stroke rehabilitation ward (group A, 112 strokes)
Number of subjects: 225
Study 6731167 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment locations (group C, 116 strokes)
Number of subjects: 225
Study 30134941 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Implementation as Usual (EIAU)
Number of subjects: 90
Study 30134941 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Intensity Coaching and Feedback (LICF)
Number of subjects: 90
Study 30134941 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Coaching and Feedback (HICF)
Number of subjects: 90
Study 30134941 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Implementation as Usual (EIAU) only
Number of subjects: 90
Study 30134941 — intervention group
Group type: COMPARATOR
Intervention: Low-Intensity Coaching and Feedback (LICF) only
Number of subjects: 90
Study 30641006 — intervention group
Group type: EXPERIMENTAL
Intervention: Hebi Formula (HF) combined with Methotrexate (MTX)
Number of subjects: 72
Study 30641006 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 72
Study 25195059 — intervention group
Group type: EXPERIMENTAL
Intervention: Model/simulation-based lecture
Number of subjects: 20
Study 25195059 — intervention group
Group type: COMPARATOR
Intervention: Didactic lecture
Number of subjects: 20
Study 22000824 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented Thompson hemiarthroplasty
Number of subjects: 200
Study 22000824 — intervention group
Group type: COMPARATOR
Intervention: Cemented Exeter Trauma Stem (ETS) hemiarthroplasty
Number of subjects: 200
Study 20862937 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with diet adjustment and aerobic exercise
Number of subjects: 61
Study 20862937 — intervention group
Group type: COMPARATOR
Intervention: Diet adjustment combined with aerobic exercise (Control)
Number of subjects: 61
Study 17914127 — intervention group
Group type: EXPERIMENTAL
Intervention: multi-antioxidant supplementation
Number of subjects: 186
Study 17914127 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 186
Study 16059622 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 and 40 microg)
Number of subjects: 1262
Study 16059622 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (40 microg)
Number of subjects: 1262
Study 16059622 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 microg)
Number of subjects: 1262
Study 16059622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1262
Study 16059622 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonate after teriparatide
Number of subjects: 1262
Study 16059622 — intervention group
Group type: EXPERIMENTAL
Intervention: No follow-up treatment after teriparatide
Number of subjects: 1262
Study 12392873 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.0 kcal/kg/week in 3 days/week
Number of subjects: 80
Study 12392873 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.0 kcal/kg/week in 5 days/week
Number of subjects: 80
Study 12392873 — intervention group
Group type: EXPERIMENTAL
Intervention: 17.5 kcal/kg/week in 3 days/week
Number of subjects: 80
Study 12392873 — intervention group
Group type: EXPERIMENTAL
Intervention: 17.5 kcal/kg/week in 5 days/week
Number of subjects: 80
Study 12392873 — intervention group
Group type: COMPARATOR
Intervention: 3 days/week of stretching and flexibility exercises for 15 to 20 min/session
Number of subjects: 80
Study 10532980 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg orally twice daily
Number of subjects: 172
Study 10532980 — intervention group
Group type: COMPARATOR
Intervention: Pivampicillin 700 mg orally twice daily
Number of subjects: 172
Study 8640144 — intervention group
Group type: EXPERIMENTAL
Intervention: Catalet C
Number of subjects: 41
Study 8640144 — intervention group
Group type: EXPERIMENTAL
Intervention: Catalet D
Number of subjects: 41
Study 8640144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 2279257 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg ibopamine
Number of subjects: 12
Study 2279257 — intervention group
Group type: COMPARATOR
Intervention: 40 mg furosemide
Number of subjects: 12
Study 2279257 — intervention group
Group type: COMPARATOR
Intervention: 200 mg ibopamine + 40 mg furosemide
Number of subjects: 12
Study 6775520 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstituted skimmed milk powder (SMP)
Number of subjects: 104
Study 6775520 — intervention group
Group type: EXPERIMENTAL
Intervention: SMP and sandwich
Number of subjects: 104
Study 6775520 — intervention group
Group type: EXPERIMENTAL
Intervention: SMP and lactase
Number of subjects: 104
Study 6775520 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted (1:1) evaporated whole milk (EM)
Number of subjects: 104
Study 6775520 — intervention group
Group type: EXPERIMENTAL
Intervention: EM and sandwich
Number of subjects: 104
Study 6775520 — intervention group
Group type: EXPERIMENTAL
Intervention: EM and lactase
Number of subjects: 104
Study 6775520 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 104
Study 30587088 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based strategies to enhance school environments
Number of subjects: 42
Study 30587088 — intervention group
Group type: COMPARATOR
Intervention: Non-SGM-specific factors
Number of subjects: 42
Study 30587088 — intervention group
Group type: COMPARATOR
Intervention: SGM-specific factors
Number of subjects: 42
Study 30587088 — intervention group
Group type: COMPARATOR
Intervention: Facilitating factors
Number of subjects: 42
Study 31503332 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin (1.5 mg/m2)
Number of subjects: 378
Study 31503332 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine (1 g/m2 over 20-120 minutes)
Number of subjects: 378
Study 28988962 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital cooling (surface ice packs, cold saline infusion, wristband reminders)
Number of subjects: 585
Study 28988962 — intervention group
Group type: COMPARATOR
Intervention: Control (usual resuscitation and transport)
Number of subjects: 585
Study 25627449 — intervention group
Group type: EXPERIMENTAL
Intervention: Strongman training
Number of subjects: 30
Study 25627449 — intervention group
Group type: COMPARATOR
Intervention: Traditional training
Number of subjects: 30
Study 23871731 — intervention group
Group type: EXPERIMENTAL
Intervention: More rapid intravenous fluid treatment
Number of subjects: 19
Study 23871731 — intervention group
Group type: COMPARATOR
Intervention: Slower intravenous fluid treatment
Number of subjects: 19
Study 21315515 — intervention group
Group type: EXPERIMENTAL
Intervention: Written disclosure
Number of subjects: 181
Study 21315515 — intervention group
Group type: EXPERIMENTAL
Intervention: Spoken disclosure
Number of subjects: 181
Study 21315515 — intervention group
Group type: COMPARATOR
Intervention: Positive control group
Number of subjects: 181
Study 21315515 — intervention group
Group type: COMPARATOR
Intervention: Neutral control group
Number of subjects: 181
Study 19369667 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 1442
Study 19369667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1442
Study 11395616 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dilator technique
Number of subjects: 50
Study 11395616 — intervention group
Group type: COMPARATOR
Intervention: Multiple-dilator technique
Number of subjects: 50
Study 11395616 — intervention group
Group type: COMPARATOR
Intervention: Both techniques
Number of subjects: 50
Study 9360734 — intervention group
Group type: EXPERIMENTAL
Intervention: Fashion magazines
Number of subjects: 39
Study 9360734 — intervention group
Group type: COMPARATOR
Intervention: News magazines
Number of subjects: 39
Study 8484698 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant oestrogen treatment
Number of subjects: 40
Study 8484698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 3318402 — intervention group
Group type: EXPERIMENTAL
Intervention: 15(R)-15-methyl prostaglandin E2 (Arbacet) (10 micrograms, 0.5 h before each meal and at bedtime)
Number of subjects: 29
Study 3318402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 28960914 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP (10 cmH2O)
Number of subjects: 21
Study 28960914 — intervention group
Group type: EXPERIMENTAL
Intervention: EPAP (10 cmH2O)
Number of subjects: 21
Study 28960914 — intervention group
Group type: COMPARATOR
Intervention: CPAP and EPAP
Number of subjects: 21
Study 27463067 — intervention group
Group type: EXPERIMENTAL
Intervention: SHIFT intervention (weight-loss competition with body weight and behavioral self-monitoring, computer-based training, and motivational interviewing)
Number of subjects: 452
Study 27463067 — intervention group
Group type: COMPARATOR
Intervention: Usual practice control
Number of subjects: 452
Study 27463067 — intervention group
Group type: EXPERIMENTAL
Intervention: SHIFT intervention
Number of subjects: 452
Study 24843959 — intervention group
Group type: EXPERIMENTAL
Intervention: Fire filiform needle combined with mild moxibustion
Number of subjects: 100
Study 24843959 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin combined with sham acupuncture
Number of subjects: 100
Study 21464154 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (1250 mg/m2 on days 1 and 8) and cisplatin (75 mg/m2 on day 1)
Number of subjects: 839
Study 21464154 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1250 mg/m2 on days 1 and 8), cisplatin (75 mg/m2 on day 1), and PF-3512676 (0.2 mg/kg on days 8 and 15 of each chemotherapy cycle)
Number of subjects: 839
Study 21464154 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine and cisplatin with PF-3512676
Number of subjects: 839
Study 21464154 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine and cisplatin
Number of subjects: 839
Study 21464154 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-3512676
Number of subjects: 839
Study 20643245 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 999
Study 20643245 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 20 to 40 mg/day
Number of subjects: 999
Study 18210954 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical telbermin (72 microg/cm2)
Number of subjects: 55
Study 18210954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 16623815 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus monotherapy (MT)
Number of subjects: 56
Study 16623815 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (TT)
Number of subjects: 56
Study 14674507 — intervention group
Group type: EXPERIMENTAL
Intervention: Pin-retained amalgam (Group A)
Number of subjects: 40
Study 14674507 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonded amalgam (Group B)
Number of subjects: 40
Study 14674507 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin composite (Group C)
Number of subjects: 40
Study 14674507 — intervention group
Group type: COMPARATOR
Intervention: High-viscosity glass-ionomer (Group D)
Number of subjects: 40